Advertisement

Urin-Marker beim Harnblasenkarzinom: Stellenwert der Urinenzymdiagnostik

  • R. Harzmann
  • D. Gericke
  • H. Groetsch
  • K.-H. Bichler

Zusammenfassung

Dem Anliegen, mit Hilfe der Urindiagnostik Hinweise auf Frühstadien des Harnblasenkarzinoms zu erhalten, wurde umfassend durch Verbesserung und Vereinfachung der Urinzytologie Rechnung getragen. Über diese Technik hinaus besteht jedoch Interesse an labordiagnostisch erfaßbaren Frühindikatoren dieses Tumors.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aeikens B (1981) Histochemische Untersuchungen an menschlichen Hamblasentumoren. Urol Int 36: 152–157PubMedCrossRefGoogle Scholar
  2. Belfiori F, Vecchio LL, Napoli E, Borzi V (1974) Increased beta-N-acetyl-glucosaminidase activity in diabetes mellitus. Clin Chem 20: 1229–1230Google Scholar
  3. Boyland E, Wallace DM, Williams DC (1955) The activity of the enzymes sulphatase and beta glucuronidase in the urine, serum and bladder tissue. Br J Cancer 9: 62–79PubMedCrossRefGoogle Scholar
  4. Carr AJ (1963) Effect of some glycosidase inhibitors on experimental tumours in the mouse. Nature 198: 1104–1105PubMedCrossRefGoogle Scholar
  5. Can AJ, Steyn JM (1972) Glycolytic enzyme activity in bladder tomours. S Afr Med J 46: 48–50Google Scholar
  6. Drahovsky D, Winkler A, Skoda J (1964) Increased urinary pseudouridine excretion following irradiation. Nature 201: 411–413PubMedCrossRefGoogle Scholar
  7. Drahovsky D, Winkler A, Skoda J (1965) Urinary excretion of pseudouridine in the course of x-ray therapy. Neoplasma 12: 561–564PubMedGoogle Scholar
  8. Droller MJ (1976) Differences in adenylate cyclase activities in murine normal cells and bladder tumor cells in tissue culture. Invest Urol 14: 249–252PubMedGoogle Scholar
  9. Dunzendorfer U, Katopodis N, Dnistrian AM, Stock CC, Schwartz MK, Whitmore WF jr (1981) Plasma lipid bound sialic acid in patients with prostate and bladder cancer. Invest Urol 19: 194–196PubMedGoogle Scholar
  10. El-Aaser AA, El-Merzabani MM, Higgy NA, Kader MMA ( 1977 a) A study on the aetiological factors of bilharzial bladder cancer in egypt. 3. Urinary beta-Glucuronidase. Eur J Cancer 15: 573–583Google Scholar
  11. El-Sewedy SM, Arafa A, Abdel-Aal G, Mostafa MH (1979) The activities of urinary alphaesterases in bilharziasis and their possible role in the diagnosis of bilharzial bladder cancer in egypt. Trans R Soc Med Hyg 72: 525–528CrossRefGoogle Scholar
  12. Fujinaga T, Nakamura J, Sangen H, Okhawa T, Kido R (1980) A new method to determine urinary aninoline compounds in patients with bladder cancer. Invest Urol 17: 416–418PubMedGoogle Scholar
  13. Goedde HW, Brunched H (1965) Beta-Aminosobutyric acid: a thin-layer chromatographic method for the quantitative estimation in human urine. Clin Chim Acta 11: 485–490PubMedCrossRefGoogle Scholar
  14. Gorrod JW (1967) The interaction of aromatic amines and some hydroxylated derivatives with cellular processes. In: Deichmann W (ed) Bladder cancer. Aesculap Publishing 6 Birmingham Alabama, p 107–121Google Scholar
  15. Guthrie D, Isah H, Latner GA (1979) Urine cyclic GMP: a possible biochemical marker for cancer. IRCS Med Sci 7: 209Google Scholar
  16. Hennessey PT, Hurst RE, Hemstreet GP, Cutter G (1981) Urinary glycosaminoglycan excretion as a biochemical marker in patients with bladder carcinoma. Cancer Res 41: 3868–3873PubMedGoogle Scholar
  17. Hurst RE, Hemstreet GP, Hennessey PT (1981) Abnormal urinary glycosaminoglycan excretion in bladder carcinoma. Am Urol Ass 76: 112Google Scholar
  18. Ichikawa T, The Japan Research Group of bladder cancer (1972) Clinical application of 2,5Di-o-Acetyl-beta-D-Glucaro-(1–4)-(6–3)-Dilactone ( SLA) to the bladder tumor with special reference to its effect on frequency of tumor recurrences. J Urol 108: 571–576Google Scholar
  19. Irving ChC (1977) Biochemically detectable tumor markers in Urine of bladder cancer patients. Cancer Res 37: 2872–2874PubMedGoogle Scholar
  20. Jüngst D, Pickel A, Stadler A, Marx FJ, Elsässer E, Karl HJ (1979) Comparative evaluation of nonesterified and total urinary cholesterol in papilloma and carcinoma of the bladder. Cancer 43: 2486–2491PubMedCrossRefGoogle Scholar
  21. Korosteleva TA, Kliucharev BV, Benteleva TA (1979) 3-Hydroxyanthranilic acid content in the urine of bladder cancer patients. Vopr Onkol 25: 36–39Google Scholar
  22. Kunze E, Schauer A (1971) Enzymhistochemische and autoradiographische Untersuchungen an Dibutylnitrosamin-induzierten Hamblasenpapillomen der Ratte. Z Krebsforsch 75: 146–160PubMedCrossRefGoogle Scholar
  23. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT (1979) N-Acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in sweden and denmark. Environ Health Perspect 29: 71–79PubMedCrossRefGoogle Scholar
  24. Maruhn D (1976) Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta 73: 453–461PubMedCrossRefGoogle Scholar
  25. Mc Gregor RF, Crawford R, Johnson DE, Brown B, Sharon MS, Johnston D (1977) Urinary amino-acid excretion. Comparison of normal individuals and patients with bladder cancer. Urology 9: 538–542CrossRefGoogle Scholar
  26. Motomiya Y, Yamada K, Matsushima S, Jjyuin M, Jriya K, Okajima E (1975) Studies on urinary isoenzymes of lactic dehydrogenase and beta-Glucuronidase in patients with bladder tumors. Urol Res 3: 41–48PubMedCrossRefGoogle Scholar
  27. Nielsen HR, Nyholm K, Sjölin K-E (1974) Relationship between urinary beta-Aminoisobutyric acid and transfer-RNA turnover in cancer patients. Cancer Res 34: 3428–3432PubMedGoogle Scholar
  28. Nyholm KK, Sjölin K-E, Hammer M, Knudsen J, Stahl D, Nielsen FIR (1975) A study on the clinical significance of urinary beta-Aminoisobutyric acid in patients with urothelial tumours. Biomedicine 22: 509–516PubMedGoogle Scholar
  29. O’Brien P, Gozzo JJ, Monaco AP (1980) Urinary proteins as biological markers: bladder cancer diagnosis versus urinary tract infection. J Urol 124: 802–803PubMedGoogle Scholar
  30. Paigen B, Ward E, Steenland K, Havens M, Sartori P (1979) Aryl hydrocarbon hydroxylase inducibility is not altered in bladder cancer patients or their progeny. Int J Cancer 23: 312–315PubMedCrossRefGoogle Scholar
  31. Pastorini P, Milano G, Toubol J, Raymond G, Cambon P, Lalanne CM (1981) The diagnostic and prognostic value of urinary polyamine measurement in bladder cancer. Urol Res 9: 13–16PubMedCrossRefGoogle Scholar
  32. Plotkin GM, Wides RJ, Gilbert SL, Wolf G, Hagen JK, Prout GR (1979) Galactosyl transferase activity in human transitional cell carcinoma lines and in benign and neoplastic human bladder epithelium. Cancer Res 39: 3856–3860PubMedGoogle Scholar
  33. Posey LE, Morgan LR (1977) Urine enzyme activities in patients with transitional cell carcinoma of the bladder. Clin Chim Acta 74: 7–10PubMedCrossRefGoogle Scholar
  34. Reutter W (1979) Testung von Serum-Glycosyltransferasen von Tumorpatienten vor and im Verlauf der Behandlung. Projekt-Status Bericht DFVLR: 309Google Scholar
  35. Sanford EJ, Drago JR, Rohner TJ, Kessler GF, Sheehan L, Lipton A (1975) Preliminary evaluation of urinary polyamines in the diagnosis of genitourinary tract malignancy. J Urol 113: 218–221PubMedGoogle Scholar
  36. Sufrin G, Tritsch GL, Mittelman A, Murphy GP (1978) Studies of lymphocyte adenosine deaminase activity in patients with renal and transitional cell carcinoma. Int Adv Surg Oncol 1: 11–28PubMedGoogle Scholar
  37. Tanaka K (1977) Beta-Glucuronidase in patients with bladder carcinoma. Acta Urol Jpn 23: 557–565Google Scholar
  38. Waalkes TPh, Gehrke ChW, Lakings DB, Zumwalt RW, Kuo KC, Jacobs SA, Borek E (1976) Beta-Aminoaciduria in patients with Burkitt’s Lymphoma. J Natl Cancer Inst 57: 435–438PubMedGoogle Scholar
  39. Wajsman Z, Williams PD, Greco J, Murphy GP (1978) Further study of fibrinogen degradation products in bladder cancer detection. Urology 12: 659–661PubMedCrossRefGoogle Scholar
  40. Wellwood JM, Ellis BG, Hall JH, Robinson DR, Thompson AE (1973) Early warning of rejection? Br Med J 2: 261–265PubMedCrossRefGoogle Scholar
  41. Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE, Jones NF (1975) Urinary N-acetyl-beta-D-Glucosaminidase activities in patients with renal disease. Br Med J 3: 408–411PubMedCrossRefGoogle Scholar
  42. Williams DR, Cartwright RA (1978) The esterase-D polymorphism in patients with diabetes or carcinoma of the bladder and a matched sample of non-donor controls. Ann Hum Biol 5: 281–284PubMedCrossRefGoogle Scholar
  43. Wirl G, Frick J (1979) Collagenase–a Marker enzyme in human bladder cancer? Urol Res 7: 103–108PubMedCrossRefGoogle Scholar
  44. Young SE, Griffin AC, Milner AN, Stehlin JS (1967) Free aminoacids and related compounds in the blood and urine of patients with malignant melanoma. Cancer Res 27: 15–17PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • R. Harzmann
    • 1
  • D. Gericke
    • 2
  • H. Groetsch
    • 2
  • K.-H. Bichler
    • 1
  1. 1.Abteilung für UrologieEberhard-Karls-Universität TübingenTübingenDeutschland
  2. 2.Hoechst AGFrankfurt/HoechstDeutschland

Personalised recommendations